Stay updated on Abrocitinib vs Dupilumab in Adult Atopic Dermatitis Clinical Trial
Sign up to get notified when there's something new on the Abrocitinib vs Dupilumab in Adult Atopic Dermatitis Clinical Trial page.

Latest updates to the Abrocitinib vs Dupilumab in Adult Atopic Dermatitis Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAdded a consolidated Locations section listing study sites across multiple regions (US, Australia, Canada, Taiwan, Spain) and removed the old per-country location blocks. The update reorganizes site information on the page to streamline finding participating sites.SummaryDifference1%

- Check21 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check42 days agoChange DetectedPubMed data source text was updated to indicate that publications are automatically filled from PubMed. The page revision version was updated from v3.2.0 to v3.3.2.SummaryDifference0.0%

- Check49 days agoChange DetectedRemoved the site-wide funding/operating-status notice from the page. The funding lapse and NIH operating-status message no longer appears on the study record.SummaryDifference0.2%

- Check71 days agoChange DetectedA new publication citation (Simpson et al., Dermatology Therapy, 2025) was added under Publications, and the earlier 'Online ahead of print' citation was removed.SummaryDifference0.2%

- Check92 days agoChange Detected- Added a government-operating-status notice and a link to official sources, indicating the page may have dynamic status information. - Updated version from v3.1.0 to v3.2.0, signaling a new release.SummaryDifference1%

- Check99 days agoChange DetectedAdds a new research citation on atopic dermatitis and updates the page to v3.1.0, replacing v3.0.2.SummaryDifference1.0%

Stay in the know with updates to Abrocitinib vs Dupilumab in Adult Atopic Dermatitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Abrocitinib vs Dupilumab in Adult Atopic Dermatitis Clinical Trial page.